Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Anovulation 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Has results × Glycoprotein Hormones, alpha Subunit × Clear all
NCT01653743 2016-01-07

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
81 enrolled 11 charts

Anovulation, Polycystic Ovary Syndrome

NCT01185704 2014-02-13

ATTAC-PCO

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
136 enrolled 21 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡